Affymax - Great opportunity for scientists and technicians | Glassdoor
There are newer employer reviews for Affymax
There are newer employer reviews for Affymax

See Most Recent

"Great opportunity for scientists and technicians"

StarStarStarStarStar
  • Work/Life Balance
  • Culture & Values
  • Career Opportunities
  • Comp & Benefits
  • Senior Management
Former Employee - Research Associate II in Mountain View, CA
Former Employee - Research Associate II in Mountain View, CA
Recommends
Positive Outlook
No opinion of CEO

I worked at Affymax full-time (More than 3 years)

Pros

Intellectually minded managers and supportive environment

Cons

Bought out by large pharma

Other Employee Reviews for Affymax

  1. "Great company work for"

    StarStarStarStarStar
    • Work/Life Balance
    • Career Opportunities
    • Comp & Benefits
    • Senior Management
    Former Employee - Research Associate in Palo Alto, CA
    Former Employee - Research Associate in Palo Alto, CA
    Recommends
    Approves of CEO

    Pros

    Great benefit
    Friendly environment
    Effective communication with management

    Cons

    Not many projects work on

    Advice to Management

    Build more strong scientific teams


  2. "Future for Affymax after Hematide is murky"

    StarStarStarStarStar
    • Work/Life Balance
    • Career Opportunities
    • Comp & Benefits
    • Senior Management
    Former Employee - Research Associate IV in Palo Alto, CA
    Former Employee - Research Associate IV in Palo Alto, CA
    Approves of CEO

    Pros

    It has a peptide drug for anemia that is likely to be approved by the FDA. The drug has efficacy, low cost of goods, and is a good candidate for Medicare preference for the treatment of anemia for the dialysis patient population. The safety profile and monthly administration of the drug is a big advantage over the currently marketed drugs for anemia.

    Cons

    No more research for new targets for new drugs in the pipeline. All work was focused on the one drug; what is next? Unless a new target is identified, there isn't much for people at Affymax to do. They already laid off 95% of the researchers, so all that history and expertise is gone. It seems to be solely focused on getting Hematide through the trials, and now that they are ready to submit data to the FDA, what happens to anyone who isn't in sales and marketing?

    Advice to Management

    Sell the company to Takeda and make some money for the stockholders, or start up R&D again. The latest worry about cardiovascular effects really caused the stock to tank. Can it be explained, or are there changes that can be made in the administration of Hematide that would ameliorate that effect? Try some positive spin in the marketing approach.

There are newer employer reviews for Affymax
There are newer employer reviews for Affymax

See Most Recent

Work at Affymax? Share Your Experiences

Affymax
  • Star
  • Star
  • Star
  • Star
  • Star
 
Click to Rate
or